CTOs on the Move

Rejuvenate Bio

www.rejuvenatebio.com

 
Rejuvenate Bio is developing novel therapies to treat aging and age-related diseases through innovative targeted gene therapies, is developing treatments to reverse aging and address multiple age-related diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Rejuvenate Bio raised $14.5M on 04/27/2021

Similar Companies

SeniorBridge Family

SeniorBridge Family is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anagenex

Discovering new medicines by combining ultra throughput biochemistry and machine learning.

VivoQuest

VivoQuest, Inc. is a Valley Cottage, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.